Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-5006 in Healthy Participants and Participants With Parkinson's Disease
NCT07310264Phase 1Recruiting
- Sponsor
- Vertero Therapeutics
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VT-5006 in Parkinson's disease (PD) (7 arms), sponsored by Vertero Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events. Started Oct 2025; status: recruiting.
02
Drugs
VT-5006
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07310264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310264.